Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Acton

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
RN Idaho|March 1, 1987
Nursing practice, intravenous medicationsR L Acton
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)|April 4, 1993
Nurses work. No students--no futureL Acton, K Tolley
Drug Discovery Today|March 20, 2010
New therapies to treat sight loss in an ageing populationDolores M Conroy, Michele L Acton
The Journal of Cell Biology|October 1, 1990
Predominance of clathrin light chain LCb correlates with the presence of a regulated secretory pathwayS L Acton, F M Brodsky
The Journal of Biological Chemistry|July 7, 1995
The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipidsA Rigotti, S L Acton, M Krieger
Psychopharmacology|October 23, 1997
Enhancement of dopamine-mediated behaviour by the NMDA antagonists MK-801 and CPP: similarities with repeated electroconvulsive shockS E Smith, L Acton, T Sharp
Molecular Medicine Today|November 24, 1999
The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?S L Acton, K F Kozarsky, A Rigotti
Congenital Anomalies|September 4, 2013
Utility of near infrared spectroscopy for the screening of the growth restricted fetusAngus L Acton, Tarun Goswami, David S McKenna
The Journal of Pharmacy and Pharmacology|September 1, 1989
Ergometrine and 5-hydroxytryptamine binding sites in rat brain and myometriumM Hollingsworth, M J Dascombe, D Price, et al.
Angewandte Chemie (International Ed. in English)|August 8, 2018
A Green BODIPY-Based, Super-Fluorogenic, Protein-Specific Labelling AgentYingche Chen, Kelvin Tsao, Sydney L Acton, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
RN Idaho|March 1, 1987
Nursing practice, intravenous medicationsR L Acton
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)|April 4, 1993
Nurses work. No students--no futureL Acton, K Tolley
Drug Discovery Today|March 20, 2010
New therapies to treat sight loss in an ageing populationDolores M Conroy, Michele L Acton
The Journal of Cell Biology|October 1, 1990
Predominance of clathrin light chain LCb correlates with the presence of a regulated secretory pathwayS L Acton, F M Brodsky
The Journal of Biological Chemistry|July 7, 1995
The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipidsA Rigotti, S L Acton, M Krieger
Psychopharmacology|October 23, 1997
Enhancement of dopamine-mediated behaviour by the NMDA antagonists MK-801 and CPP: similarities with repeated electroconvulsive shockS E Smith, L Acton, T Sharp
Molecular Medicine Today|November 24, 1999
The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?S L Acton, K F Kozarsky, A Rigotti
Congenital Anomalies|September 4, 2013
Utility of near infrared spectroscopy for the screening of the growth restricted fetusAngus L Acton, Tarun Goswami, David S McKenna
The Journal of Pharmacy and Pharmacology|September 1, 1989
Ergometrine and 5-hydroxytryptamine binding sites in rat brain and myometriumM Hollingsworth, M J Dascombe, D Price, et al.
Angewandte Chemie (International Ed. in English)|August 8, 2018
A Green BODIPY-Based, Super-Fluorogenic, Protein-Specific Labelling AgentYingche Chen, Kelvin Tsao, Sydney L Acton, et al.
Pageof 3